<DOC>
	<DOCNO>NCT02738073</DOCNO>
	<brief_summary>Tranexamic acid ( TA ) inhibit fibrinolysis bind lysine binding-sites plasminogen fibrin . Fibrinolysis stimulate surgical trauma , administration TA show effective decrease blood loss intra-operatively immediate post-operative period elective hip knee arthroplasty patient . Both time dosing TA investigate patient . Subsequent blood transfusion rate also show decrease result TA administration . Despite support TA utilization exist arthroplasty literature , data scarce regard administration surgical treatment hip fracture . This patient population high risk transfusion due symptomatic post-operative anemia . This study aim investigate whether TA 's advantageous effect arthroplasty patient population extrapolate unstable , heterogeneous hip fracture patient population . If study able show difference blood loss transfusion requirement , long term implication regard cost mortality significant .</brief_summary>
	<brief_title>Effects Tranexamic Acid Blood Loss Transfusion Requirement Following Hip Fracture</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Patients admit Bryn Mawr Hospital fracture femoral neck , intertrochanteric region , subtrochanteric region femur consider study . Exclusion criterion include age 18 allergy TA know current history venous thromboembolism ( VTE ) history know coagulopathy bleed disorder current subarachnoid hemorrhage previous history seizure current use estrogen/progesterone therapy renal failure define creatinine clearance le 30 ml/min4 multiple fracture pregnant breastfeed woman plan nonoperative management fracture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>